Mark A. Ratner
#178,973
Most Influential Person Now
Mark A. Ratner's AcademicInfluence.com Rankings
Mark A. Ratnerchemistry Degrees
Chemistry
#5450
World Rank
#6633
Historical Rank
Nanotechnology
#198
World Rank
#198
Historical Rank
Physical Chemistry
#890
World Rank
#950
Historical Rank
Download Badge
Chemistry Physics
Why Is Mark A. Ratner Influential?
(Suggest an Edit or Addition)Mark A. Ratner's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Year in Review (1990) (537)
- Conference on Molecular Electronics: Science and Technology, Puerto Rico, 14-18 December 1997: Preface (1998) (139)
- Genentech discloses safety concerns over Avastin (2004) (104)
- Pfizer reaches out to academia—again (2011) (45)
- Genentech's glyco-engineered antibody to succeed Rituxan (2014) (34)
- Pfizer stakes a claim in plant cell–made biopharmaceuticals (2010) (29)
- FDA backs clinician-free AI imaging diagnostic tools (2018) (24)
- Protein Expression in Yeast (1989) (24)
- Microbial cocktails join fecal transplants in IBD treatment trials (2015) (23)
- IL-17–targeting biologics aim to become standard of care in psoriasis (2015) (23)
- Earth: The Sequel: The Race to Reinvent Energy and Stop Global Warming (2008) (23)
- A New Era for Genentech, And So It Goes (1990) (18)
- Pfizer settles largest ever fraud suit for off-label promotion (2009) (18)
- Off-label or off-limits? (2008) (18)
- IL-1 trap go-ahead (2008) (18)
- FDA pharmacogenomics guidance sends clear message to industry (2005) (18)
- Fecal transplantation poses dilemma for FDA (2014) (18)
- Survey and Opinions: Barriers to Field-Testing Genetically Modified Organisms (1990) (17)
- Biogen's early Alzheimer's data raise hopes, some eyebrows (2015) (17)
- Seres's pioneering microbiome drug fails mid-stage trial (2016) (15)
- Annals of the New York Academy Sciences: Introduction (2002) (14)
- Despite the Best of Intentions (1991) (14)
- FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label (2017) (14)
- Spotlight focuses on protein-misfolding therapies (2009) (13)
- IBM's Watson Group signs up genomics partners (2015) (13)
- Small biotech steers HDAC inhibitor to clinic (2014) (12)
- Next-generation AMD drugs to wed blockbusters (2014) (12)
- Roche Making Up for Past IL-2 Missteps (1990) (10)
- Off-the-shelf CAR-T therapy induces remission in child with ALL (2016) (10)
- Setback for JAK2 inhibitors (2014) (10)
- FDA pushes for control over laboratory-developed tests (2014) (9)
- Fearful of Avastin's fate, Genentech asks for unusual hearing (2011) (9)
- Human Genome Sciences trial data wow lupus community (2009) (9)
- Genentech's PD-L1 agent approved for bladder cancer (2016) (9)
- IL-1 trap go-ahead (2008) (9)
- Crop Biotech '89: Research Efforts are Market Driven (1989) (8)
- Microbial cocktails raise bar for C. diff. treatments (2020) (8)
- FDA panel votes to pull Avastin in breast cancer, again (2011) (8)
- Pharma swept up in biogenerics gold rush (2009) (8)
- First multi-gene NGS diagnostic kit approved (2017) (8)
- Myriad decision aftershocks ripple through biotech (2013) (8)
- Heart failure gene therapy disappoints but experts keep the faith (2015) (7)
- Roche plans for more convenient-to-use Herceptin and Rituxan (2010) (7)
- Jury out on liquid biopsies for cancer (2018) (6)
- Shire punts on bioscaffolds for cell-based regenerative medicine (2012) (6)
- Conference Report: Molecular Electronics–Science and Technology. 14–18 December 1997, Humacao, Puerto Rico (1998) (6)
- Big pharma upheavals cast shadow across biotech sector (2012) (5)
- Landmark approvals in idiopathic pulmonary fibrosis (2014) (5)
- FDA approves three different multiple myeloma drugs in one month (2016) (5)
- Looking for solid ground along the Critical Path (2006) (5)
- Recombinant thrombin approved (2008) (5)
- Next-generation sequencing tests to become routine (2018) (5)
- First PDE4 inhibitor for psoriasis hits the market but impact is uncertain (2014) (5)
- Waiting For Antisense To Deliver (1991) (5)
- Competition drives agriculture's genomics deals (1998) (5)
- Should platform companies move toward products? (1999) (4)
- A turbulent year at the agency (2006) (4)
- Benlysta makes history (2011) (4)
- Patients with porphyria bask in sunlight of FDA approval (2019) (4)
- Complement inhibitors finally find orphan niches (2006) (3)
- EPO, Factor VIII Shockers (1991) (3)
- Eylea approval transforms Regeneron (2012) (3)
- Data on BRMs Impress New FDA Committee (1990) (3)
- Resuscitated deCODE refocuses on diagnostics (2010) (3)
- Genzyme's Lumizyme clears bioequivalence hurdles (2009) (3)
- Publisher Correction: Light-activated genetic therapy to treat blindness enters clinic (2021) (3)
- Cancer Pathways' target not validated by clinical results (1999) (3)
- Earlier stage biotechs attract partners (2005) (3)
- Toward Using In Vitro Toxicology in the Drug Approval Process (1990) (3)
- Roche spends $1 billion on Foundation Medicine's tumor profiling (2015) (3)
- Approval of first tumor gene panel sends shockwaves through labs (2018) (3)
- Roche swallows Ariosa, grabs slice of prenatal test market (2015) (2)
- Novartis eyes oral MS drug as potential blockbuster (2010) (2)
- Power to the Pedagogues (1995) (2)
- Maturing biotechs turn to pharma's markets (2005) (2)
- Odds still favor Novartis heart failure drug Serelaxin (2014) (2)
- Fabry drug march-in denied (2011) (2)
- China steps up US biotech intellectual property land grab (2008) (2)
- FDA approves first single-dose antimalarial (2018) (2)
- Celgene wagers on Sutro's cell-free platform to ramp up bispecifics (2014) (2)
- Shire dumps Dynepo (2008) (2)
- Of EPA, Risks, and Rule Making (1989) (2)
- Neuroimaging heats up (2005) (2)
- The Mo Cell Case Moves Back into the Courts (1988) (2)
- Industry shrugs off NIH consulting ban (2005) (2)
- FDA to relax grip on at-home genetic tests, but concerns linger (2018) (2)
- The gatekeepers of effectiveness (2012) (2)
- As products enter clinic...scientists shown the door. (2004) (2)
- Gilead bets big on Nimbus' fatty liver disease drug (2016) (2)
- AN APPRECIATION OF THE STOICHIOMETRIC NUMBER METHOD FROM THE VIEWPOINT OF QUANTUM STATISTICAL MECHANICS (1973) (2)
- Genzyme-Sanofi buyout is second largest biotech deal ever (2011) (2)
- Progress with Pegylation (1990) (2)
- Pharma partners with efforts to pool patient genotype and phenotype data (2014) (1)
- Profile: Daphne Zohar (2006) (1)
- Top Tier Strong Entering '91 (1991) (1)
- HIV treatment study clears virus, sends Sangamo stock soaring (2014) (1)
- Tribute to George C. Schatz. (2009) (1)
- Erythropoietins locked into risk management program (2010) (1)
- GSK buys partner Human Genome Sciences (2012) (1)
- The Analysts Take Aim, Biotech Fires Back (1988) (1)
- Ian Frazer (2007) (1)
- T-PA Trials, Tribulations, and Litigation (1990) (1)
- Genentech: Don't Sell the Company Short (1989) (1)
- Reality check for device-drug convergence (2007) (1)
- Identifying Quantitative Traits in Plants (1990) (1)
- Dealing with Large Companies (1989) (1)
- Strata rolls out drug-matching service, offers free tumor profiling (2016) (1)
- Heart failure gene therapy disappoints but experts keep the faith (2015) (1)
- Syrrx acquisition signals maturation of structure-based discovery (2005) (1)
- Faster approval for breakthrough devices (2014) (1)
- Biotechs opt for alternative floatation strategy (2012) (1)
- World Bank to Help Weave a ‘Seamless Web’ (1989) (1)
- Synergen Suddenly a Hit with Investors (1989) (1)
- Shire bags NPS, including newly approved biologic for hypoparathyroidism (2015) (1)
- New IGF drug stirs competition in growth factor segment (2005) (1)
- DNA Probes: The Market Versus the Magic (1988) (1)
- Crossing the line (2010) (1)
- Product Approvals in the Current Environment (1989) (1)
- Can the Antisense Message Be Delivered? (1989) (1)
- ARRA boosts cancer programs but impact on personalized medicine unclear (2009) (1)
- Genzyme resumes shipping as Sanofi-aventis hovers (2010) (1)
- cDNA is patentable, but not genes (2013) (1)
- Alexion pays big for Synageva's rare disease drug candidate (2015) (1)
- Trade groups laud Gottlieb FDA choice, silent on NIH cutback (2017) (1)
- Key Structure of Viral Enzyme Solved (1991) (1)
- Light-activated genetic therapy to treat blindness enters clinic (2021) (1)
- Pivotal FDA/Exelixis dispute (2012) (0)
- Baxter carves out biopharma division (2014) (0)
- Amgen cholesterol antibody feud could kill key IP rule (2017) (0)
- Novo-Nordisk Expands in U.S. (1989) (0)
- Cochrane meta-analysis on alpha-1 antitrypsin prompts furor. (2010) (0)
- Amgen best-seller challenged by generics (2013) (0)
- Digesting Genzyme's Integrated Deal (1989) (0)
- Competition in the marketplace. t-PA trials, tribulations, and litigation. (1990) (0)
- Who Owns the Rights to Human Tissues? (1988) (0)
- New Weapons, New War: Homeland Security, International Defense and Nanotechnology (2003) (0)
- Maxims for Management and Investing (1990) (0)
- ICOS Jump-Starts with $33 Million Funding (1990) (0)
- Experimentation in Space Resumes—Finally (1988) (0)
- Nova Settles into a New Orbit (1990) (0)
- Opinion: Biotech Back to Basics (1990) (0)
- John Anthony Pople (2005) (0)
- Scripps boosts research coffers by selling reagents to Sigma-Aldrich (2013) (0)
- Preface (1998) (0)
- Corrigendum: FDA panel votes to pull Avastin in breast cancer, again (2012) (0)
- Marketing Biotech Products: Establishing ‘The Rules of the Game’ (1988) (0)
- Genomics pioneer gets its first drug (2017) (0)
- Need for Money Spurs Lobby (1989) (0)
- Avastin as good as Lucentis (2011) (0)
- New CEO appointment reveals Merck's response to setbacks (2005) (0)
- Amgen's Japan deal (2008) (0)
- Applying Today's Biotechnologies (1990) (0)
- Biotech: Experimental Subject (1989) (0)
- The H & Q View of the Life Sciences Arena (1990) (0)
- Celgene shells out for antisense drug (2014) (0)
- FDA to oversee reporting of clinical trials (2012) (0)
- Opinion: Bandshift (1990) (0)
- Sanofi/Genzyme hostile (2010) (0)
- Marcus Joins the Nobel Ranks (0)
- Third World Science Groups Form Network (1989) (0)
- Autobiography of Mark A. Ratner (2010) (0)
- Regional Development: The Role and Effectiveness of Governmental Agencies (1989) (0)
- Novel initiative seeks genetic causes of diabetes risk (2004) (0)
- Dyax backs albumin (2008) (0)
- FDA sets hierarchy for biosimilars evidence (2014) (0)
- Opinion: Was It the Conference or the Climate? (1989) (0)
- Tribute to Abraham Nitzan. (2019) (0)
- Chronic fatigue first on FDA agenda (2013) (0)
- CSFs' Infection-Fighting Ability Recognized (1991) (0)
- When Microheterogeneity Matters (1991) (0)
- Biotech Business Guide Gives Little Guidance (1989) (0)
- Erratum: Table of Contents (2009) (0)
- Dynamic Market Emerging for Molecular Modeling (1989) (0)
- Introduction (2002) (0)
- Transgenic Sciences Making a Big Splash (1990) (0)
- Thermo Fisher vies for Life Technologies' sequencing market (2013) (0)
- Later-Stage Financing in the Doldrums (1989) (0)
- GSK adopts antisense (2009) (0)
- Sanofi drops MannKind's inhaled insulin (2016) (0)
- Alliances Validate Liposome Co. Work (1991) (0)
- Erratum: Resuscitated deCODE refocuses on diagnostics (2010) (0)
- Biotech in Full Bloom at Coast Conference (1989) (0)
- Straight talk with...Joseph Schwartz (2012) (0)
- Publisher Correction: Light-activated genetic therapy to treat blindness enters clinic (2021) (0)
- Examining Biotech's Global Economic Role (1989) (0)
- Amgen, GI Heading for Patent Showdown (1989) (0)
- Profile: Einer Elhauge (2006) (0)
- Playing EPO-Litics at the FDA (1990) (0)
- The Cetus Experience: Troubles with Clinical Trials Design & Data Presentation (1990) (0)
- IL-2 in the Market: Winners and Losers (1990) (0)
- Immunophilin Structure Via NMR (1991) (0)
- Profile: Jean Deleage (2005) (0)
- Biotech Executives Exude Confidence (1991) (0)
- Trade groups laud Gottlieb FDA choice, silent on NIH cutback (2017) (0)
- Kits herald new wave of genomics diagnostics for cancer (2012) (0)
- PCG Microgravity Experiments Flying High (1990) (0)
- Trade Association Sets 1989 Priorities (1989) (0)
- Chiron Greets the Decade with Diagnostics (1990) (0)
- An Analysis of the Nutritional Adequacy of Mass-Marketed Vegan Recipes (2023) (0)
- A Congressional Mandate for Military Research (1989) (0)
- Ag Investors Growing Excited (1989) (0)
- Immunex Turns a Triple Play (1989) (0)
This paper list is powered by the following services:
